Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
ATTAIN-1 Phase 3 (Orforglipron for Obesity)
TRANSCEND-T2D-1 (NCT06354660) reported topline results on March 19, 2026, with full publication in The Lancet in June 2026
These companies have built their entire business model on foods that hijack your appetite, making you eat more than your body needs
Dose: Dosage varies depending on your specific needs however, anything between 300-1000mg a day for women and 200mg a day for men may be recommended
Retatrutide Weight Loss Results Trial Data and FDA Status The major headline came from the TRIUMPH-1 Phase 3 trial
US$ 28.91
US$ 21.70
US$ 21.69
US$ 23.11
US$ 25.65
